Role of oral cyclophosphamide in the treatment of giant cell arteritis

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1677-1686

  Quartuccio, Luca ^a   Maset, Marta ^a   De maglio, Giovanna ^a   Pontarini, Elena ^a   Fabris, Martina ^a   Mansutti, Elisa ^a   Mariuzzi, Laura ^a   Pizzolitto, Stefano ^a   Beltrami, Carlo Alberto ^a   De vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Arteritis; Cyclophosphamide; Giant cell; Glucocorticoids; Interferon; Temporal

Indexed keywords

CD3 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 17; METHOTREXATE; PREDNISONE;

AB INITIO CALCULATION; ACUTE HEPATITIS; ADULT; AGED; ALOPECIA; APLASTIC CRISIS; ARTICLE; BLOOD VESSEL BIOPSY; BRONCHITIS; CANDIDIASIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INFLAMMATORY INFILTRATE; MALE; NAUSEA; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OESOPHAGEAL CANDIDOSIS; ORAL MUCOSITIS; PANCYTOPENIA; PRIORITY JOURNAL; PRURITUS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TEMPORAL ARTERY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84865333685     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes127     Document Type: Article

References (35)

1. Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc 2006;81:1071-83.
2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
3. Weyand CM, Ma-Krupa W, Pryshchep O et al. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 2005;1062:195-208.
4. Hunder GG. Giant cell (temporal) arteritis. Rheum Dis Clin North Am 1990;16:399-409.
5. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.
6. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23.
7. Jover JA, Hernandez-Garcia C, Morado IC et al. Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 2001;134:106-14.
8. Cantini F, Niccoli L, Salvarani C et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-5.
9. Airo P, Antonioli CM, Vianelli M et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology 2002;41:347-9.
10. Tan AL, Holdsworth J, Pease C et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-4.
11. Ahmed MM, Mubashir E, Hayat S et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007;26:1353-5.
12. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.
13. Beyer C, Axmann R, Sahinbegovic E et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011;70:1874-5.
14. Seitz M, Reichenbach S, Bonel HM et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156.
15. Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient meta-analysis. Arthritis Rheum 2007;56: 2789-97.
16. Hoffman GS, Hellmann DB, Guillevin L et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
17. Hoffman GS, Cid MC, Rendt-Zagar KE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30.
18. Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biol Ther 2004;3: 1212-3.
19. De Vita S, Tavoni A, Jeracitano G et al. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992;232:373-5.
20. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906-15.
21. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell (temporal) arteritis. Arthritis Rheum 1990; 33:1122-8.
22. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century -a disease of older patients. Rheumatology 2005;44:495-501.
23. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68: 310-7.
24. Henes JC, Muller M, Pfannenberg C, Kanz L, Kotter I. Cyclophosphamide for large-vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29(Suppl. 64):S43-8.
25. Brack A, Geisler A, Martinez-Taboada VM et al. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997;3: 530-43.
26. Weyand CM, Ma-Krupa W, Pryshchep O et al. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 2005;1062:195-208.
27. Krupa WM, Dewan M, Jeon MS et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002;161: 1815-23.
28. Ma-Krupa W, Jeon MS, Spoerl S et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004;199: 173-83.
29. Wagner AD, Wittkop U, Prahst A et al. Dendritic cells co-localize with activated CD4+ T cells in giant cell arteritis. Clin Exp Rheumatol 2003;21:185-92.
30. Ly KH, Régent A, Tamby MC, Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev 2010;9:635-45.
31. Radojcic V, Bezak KB, Skarica M et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother 2010;59: 137-48.
32. Karni A, Balashov K, Hancock WW et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004;146: 189-98.
33. Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsy. Clin Exp Rheumatol 2009;27(1 Suppl. 52):S10-3.
34. Généreau T, Lortholary O, Pottier MA et al. Temporal artery biopsy: a diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum 1999;42:2674-81.
35. Esteban MJ, Font C, Hernández-Rodríguez J et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum 2001;44: 1387-95.